Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma

Pralatrexate is a novel antifolate approved in the USA for the treatment of relapsed or refractory peripheral T‐cell lymphoma. To assess its safety, efficacy, and pharmacokinetics in Japanese patients with this disease, we undertook a phase I/II study. Pralatrexate was given i.v. weekly for 6 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Nagai, Hirokazu, Maeda, Yoshinobu, Nakane, Takahiko, Shimoyama, Tatsu, Nakazato, Tomonori, Sakai, Rika, Ishikawa, Takayuki, Izutsu, Koji, Ueda, Ryuzo, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623731/
https://www.ncbi.nlm.nih.gov/pubmed/28771889
http://dx.doi.org/10.1111/cas.13340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623731/
https://www.ncbi.nlm.nih.gov/pubmed/28771889
http://dx.doi.org/10.1111/cas.13340

Ejemplares similares